Physician profile
Marena Arnold
NPI 1467842344
$8,395.74
in general payments reported to CMS, 2019-2025
31 companies · $1,302 in 2025
The $1,302 reported for 2025 was more than what 89% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,212 · 2022: $2,059 · 2023: $1,490 · 2024: $1,332 · 2025: $1,302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,035 · Education: $88.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,035.46 |
| Education | $88.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,706.48 | 2021-2025 | Cardiomems, Amplatzer Amulet, Thoratec Heartmate 3 Lvas Implant Kit |
| Novartis Pharmaceuticals Corporation | $1,078.29 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $802.12 | 2021-2025 | Brilinta, Wainua, Farxiga |
| Alnylam Pharmaceuticals INC. | $707.13 | 2021-2025 | Onpattro, Amvuttra |
| Merck Sharp & Dohme LLC | $561.67 | 2022-2025 | Verquvo, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $561.33 | 2021-2025 | Jardiance |
| Amgen INC. | $485.82 | 2021-2024 | Repatha |
| Pfizer INC. | $472.66 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $271.97 | 2023-2025 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $255.71 | 2021-2025 | Opsumit, Uptravi, Opsynvi |
| Impulse Dynamics (USA) INC. | $216.30 | 2022-2025 | Optimizer |
| Esperion Therapeutics, INC. | $146.89 | 2021-2023 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $123.81 | 2022-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $123.67 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $110.79 | 2025 | Evkeeza |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $91.67 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $87.25 | 2021-2022 | |
| Cvrx, INC. | $72.06 | 2024-2025 | Barostim Neo System |
| Edwards Lifesciences Corporation | $65.25 | 2022-2025 | Sapien 3 Ultra Resilia |
| Chiesi USA, INC. | $64.00 | 2021-2022 | |
| Boston Scientific Corporation | $61.35 | 2021-2024 | Watchman Flx |
| Amarin Pharma, INC. | $57.38 | 2022 | |
| United Therapeutics Corporation | $56.34 | 2021-2022 | |
| Bridgebio Pharma, INC. | $41.93 | 2025 | Attruby |
| Kowa Pharmaceuticals America, INC. | $28.86 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $27.80 | 2023-2024 | Inpefa |
| Sanofi-Aventis U.S. LLC | $27.44 | 2023-2024 | |
| Medtronic, INC. | $26.28 | 2025 | Solitaire X |
| Ionis Pharmaceuticals, INC. | $24.01 | 2025 | Tryngolza |
| Daiichi Sankyo INC. | $21.91 | 2023 | Injectafer |
| Novo Nordisk INC | $17.57 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marena Arnold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.